|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Enhanced killing of B lymphoma cells by granulocyte colony - stimulating factor - primed effector cells and Hu1D10-a humanized human 1eucocyte antigen DR antibody显示文摘 | Stockmeyer B Schiller M Repp R | 2002 | Br J Haematol2002，8，4： | 1 |
| 2 | Docetaxel and continuous-infusion fluorouracil versus epirubicin,cisplatin,and fluorouracil for advanced gastric adenocarcinoma:a randomized phase Ⅱ study显示文摘 | Thuss-Patience PC Kretzschmar A Repp M | 2005 | Journal of Clinical Oncology:official journal of the American Society of Clinical Oncology2005，23，3： | 1 |
| 3 | Docetaxel and continuous-infusion fluorouracil veins epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized Phase II study显示文摘 | Thuss-Patience P Kretzschmaer A Repp M | 2005 | J Clin Oncol2005，23，3： | 1 |
| 4 | The addition of rituximab to a combination of fludarabine,cyclophosphamide,mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas:results of a prospective randomized study of the german low-grade lymphoma study group显示文摘 | Forstpointner R Dreyling M Repp R | 2004 | Blood2004，104，10： | 1 |
| 5 | The addition of rituximab to a combination of fludarabine,cyclophosphamide,mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas显示文摘 | Forstpointner R Drevling M Repp R | 2004 | Blood2004，104，10： | 1 |
| 6 | Docetaxel and continuous-infusion fluorouracil verus epimbicin, cisplatin and fluorouracil for advanced gastric adenocarcinoma: a randomized phase Ⅱ study显示文摘 | Thuss-Patience P Kretzschmaer A Repp M | 2005 | J Clin Oncol2005，23，3： | 1 |
| 7 | Immuno- phenotyping is an independent factor for risk stratification in AML 显示文摘 | Repp R Schaekel U Helm G Thiede C Soucek S Pascheberg U Wandt H Aulitzky W Bodenstein H Sonnen R Link H Ehninger G Gramatzki M AML- SHG Study Group | 2003 | Cytometry B Clin Cytom2003，53，1： | 1 |
| 8 | Doceaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: A randomized phase Ⅱ study显示文摘 | Thuss-Patience PC Kretzschmar A Repp M | 2005 | J Clin 0ncol2005，23，： | 1 |
| 9 | The addition of rituximab to a combination of fludarabine, cyclophos- phamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group显示文摘 | Forstpointner R Dreyling M Repp R | 2004 | Blood2004，104，10： | 1 |
| 10 | Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenoearcinoma: a randomized phase Ⅱ study显示文摘 | Thuss-Patience PC Kretzschmar A Repp M | 2005 | J Clin Oncol2005，23，3： | 1 |
| 11 | Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study显示文摘 | Thuss-Patience PC Kretzschmar A Repp M | 2005 | J Clin Oncol2005，23，3： | 1 |
| 12 | The addition of ritaximab to a combination of fudarabine,cyclophosphamide,mitoxantrone(FCM)significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas:results of a prospective randomized study of the German Low-Grade Lyphoma Study Group显示文摘 | Forstpointner R Dreyling M Repp R | 2004 | Blood2004，，104： | 1 |
| 13 | Docetaxeland continuous-infusion fluorouracil versus epirubicin,cisplatin,and fluorouracil for advanced gastric adenocarcinoma:a random-ized phase II study 显示文摘 | Thuss-Patience PC Kretzschmar A Repp M | 2005 | J Clin Oncol2005，23，3： | 1 |
| 14 | The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas - results of a prospective randomized study of the German low grade lymphoma study group (GLSG) 显示文摘 | Forstpointner R Dreyling M Repp R | 2004 | Blood2004，104，： | 1 |
| 15 | The addition of rituximab to a bombination of fludarabine,cyclphosphamide,mitoxantrone (FCM) significantly increases the response rage and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas:results of a prospective randomized study of the german lowgrade lymphoma study group显示文摘 | Forstopointner R Dreyling M Repp R | 2004 | Blood2004，104，： | 1 |
| 16 | Docetaxel and continuous-infusion fluorouracil versus epirubicin,cisplatin,and fluorouracil for advanced gastric adenocarcinoma:a randomized phase Ⅱ study显示文摘 | Thuss-Patience PC Kretzschmar A Repp M Kingreen D | 2005 | J Clin Oncol2005，23，： | 1 |
| 17 | The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group显示文摘 | FORSTPOINTNER R DREYLING M REPP R | 2004 | Blood2004，104，： | 1 |
| 18 | The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group 显示文摘 | Forstpointner R Dreyling M Repp R | 2004 | Blood2004，104，10： | 1 |
| 19 | Docetaxel and continuous infusion fluorouracil versus epimbicin, cisplatin, and flu- orouracil foradvanced gastric adenocarcinoma: a randomized phase Ⅱ study 显示文摘 | Thuss - Patience PC Kretzschmar A Repp M | 2005 | J Clin Oncol2005，23，： | 1 |
| 20 | Docetaxel and continuous, infusion fluorouracil versus epimbicin, cisplatin, and flu- orouracil foradvanced gastric adenocarcinoma : a randomized phase II study显示文摘 | Thuss - Patience PC Kretzschmar A Repp M | 2005 | J Clin Oncol2005，23，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员